8-KLeadership ChangesExhibits & Filings

Elevance Health, Inc. 8-K Report, Executive Changes (Oct 25, 2022)

Filed October 25, 2022For Securities:ELV

Summary

Elevance Health, Inc. (ELV) filed an 8-K on October 24, 2022, to announce a key board-level change. The company elected Deanna Strable-Soethout as an independent director, effective November 1, 2022. This appointment brings a new perspective to the Board and strengthens its oversight capabilities. Ms. Strable-Soethout's appointment is significant as she has been designated as an "audit committee financial expert," indicating her financial acumen and suitability for a critical role in financial governance. She will serve on both the Audit and Governance Committees, further reinforcing the company's commitment to robust financial reporting and corporate responsibility. Investors can anticipate that her expertise will contribute to the Board's strategic decision-making and fiduciary duties.

Key Highlights

  • 1Elevance Health appointed Deanna Strable-Soethout as an independent director to its Board, effective November 1, 2022.
  • 2Ms. Strable-Soethout will serve a term expiring at the 2023 annual meeting of shareholders.
  • 3She has been appointed to serve on the Audit and Governance Committees of the Board.
  • 4The Board has determined Ms. Strable-Soethout qualifies as an "audit committee financial expert."
  • 5Her appointment is intended to enhance the Board's financial oversight and governance expertise.
  • 6Compensation for Ms. Strable-Soethout will follow the company's standard program for non-employee directors.

Frequently Asked Questions

Deanna Strable-Soethout has been elected as an independent director to Elevance Health's Board. Her appointment is significant because she brings valuable expertise to the Board, particularly in financial matters, as she has been designated an 'audit committee financial expert.' She will also serve on the Audit and Governance Committees, strengthening the company's oversight.

Ms. Strable-Soethout will be a member of the Audit Committee and the Governance Committee of the Elevance Health Board of Directors.

Ms. Strable-Soethout will receive compensation in accordance with Elevance Health's standard compensation program for non-employee directors. Details of this program are available in the company's Quarterly Report on Form 10-Q for the period ended June 30, 2022.

According to the filing, there are no arrangements or understandings between Ms. Strable-Soethout and any other person related to her election. Furthermore, she has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K.